Loading
Built the Network Genomic Medicine that brought molecular testing to lung cancer patients across Germany, and led the capmatinib GEOMETRY trial.
Jürgen Wolf is Medical Director of the Lung Cancer Group Cologne and Head of Network Genomic Medicine at Uniklinik Köln (CIO). His specialisms are lung cancer, molecular diagnostics networks and MET- and KRAS-targeted therapy, using comprehensive genomic profiling. He founded Network Genomic Medicine, which brought molecular testing to lung cancer patients across Germany by sequencing non-small-cell lung cancer across hundreds of centres. He was principal investigator of GEOMETRY mono-1, the New England Journal of Medicine trial of capmatinib in MET exon 14-mutated or MET-amplified non-small-cell lung cancer. His publications are listed on PubMed.
| Title | Journal | Year |
|---|---|---|
| Capmatinib in MET exon 14-mutated or MET-amplified non-small-cell lung cancer (GEOMETRY mono-1) | NEJM | 2020 |
| DeLLphi-301: tarlatamab, a DLL3-targeting T-cell engager, in previously treated small-cell lung cancer | New England Journal of Medicine | 2023 |
Patients with small-cell lung cancer that has relapsed after chemotherapy now have a drug that works far better than topotecan or lurbinectedin, and it is the first T-cell engager approved for a solid tumour. Treatment requires inpatient monitoring for the first doses because of cytokine release syndrome, which most centres now manage on a short-stay basis. It does not yet apply to first-line treatment, where trials are ongoing.
ASCEND-4 gave ceritinib its 2017 US first-line approval and showed that a second-generation ALK inhibitor beats chemotherapy in untreated disease. In practice alectinib, brigatinib and lorlatinib, tested against crizotinib rather than chemotherapy, became the usual first-line choices, partly because ceritinib's gut side effects at 750 mg fasted were hard to live with.
Shares Uniklinik Köln (CIO), nationales Netzwerk Genomische Medizin Lungenkrebs, Comprehensive genomic profiling, Non-small-cell lung cancer.
Shares First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study, ASCEND-4, Non-small-cell lung cancer.
Shares First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study, ASCEND-4, DeLLphi-301: tarlatamab, a DLL3-targeting T-cell engager, in previously treated small-cell lung cancer, Non-small-cell lung cancer.
Shares First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study, ASCEND-4.
Shares Capmatinib & tepotinib, MET, Non-small-cell lung cancer.
Shares First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study, ASCEND-4, Non-small-cell lung cancer.
Shares Capmatinib & tepotinib, MET, Non-small-cell lung cancer.
Shares nationales Netzwerk Genomische Medizin Lungenkrebs, Non-small-cell lung cancer.